Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342639 · ClinicalTrials.gov registry record · Phase 4
Rifaximin Therapy in Chronic Kidney Disease
A Phase 4 study of Chronic Kidney Disease, sponsored by Jason Stubbs, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT02342639: Completed Phase 4 study of Chronic Kidney Disease, sponsored by Jason Stubbs, MD.
NCT02342639 is a Phase 4 study of Chronic Kidney Disease that has completed, run by Jason Stubbs, MD. The registered enrollment target is 38 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342639, a Phase 4 study of Chronic Kidney Disease, has completed, sponsored by Jason Stubbs, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rifaximin
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 4 |
What the finished NCT02342639 record still lists
NCT02342639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02342639 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02342639 about?
NCT02342639 is a clinical study titled "Rifaximin Therapy in Chronic Kidney Disease". The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.
What is the current status of trial NCT02342639?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2015-06. Estimated completion is 2019-03-01.
What conditions does trial NCT02342639 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT02342639?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT02342639?
This trial is sponsored by Jason Stubbs, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342639 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02342639's enrollment target sits among peer trials
38 79th of 101 higher than 23 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
RECRUITING · Phase 4
-
Empagliflozin Treatment in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia